Bristol Myers Squibb announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with
Bristol Myers Squibb has announced that Cristian Massacesi, M.D., will begin his new role as Executive Vice President, Chief Medical Officer, and Head of Development
Rapidly growing lung health company aims to redefine early diagnosis and precision lung cancer care using multi-modal artificial intelligence (AI). Optellum, a global leader in
Bristol Myers Squibb announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive
The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools OpenFold, a non-profit AI research consortium dedicated to creating free, open-source software tools
MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, announced that Brian Shuster will join
Jumo Health – a global provider of age-appropriate, culturally relevant medical education resources – announced it is a finalist for the Fierce DEI Award for helping
